These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 15842551)

  • 1. Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males.
    Stass H; Kubitza D; Möller JG; Delesen H
    Br J Clin Pharmacol; 2005 May; 59(5):536-41. PubMed ID: 15842551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery.
    De Smet J; Colin P; De Paepe P; Ruige J; Batens H; Van Nieuwenhove Y; Vogelaers D; Blot S; Van Bocxlaer J; Van Bortel LM; Boussery K
    J Antimicrob Chemother; 2012 Jan; 67(1):226-9. PubMed ID: 21987240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers.
    Burkhardt O; Stass H; Thuss U; Borner K; Welte T
    Clin Pharmacokinet; 2005; 44(9):969-76. PubMed ID: 16122283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis.
    Stass H; Rink AD; Delesen H; Kubitza D; Vestweber KH
    J Antimicrob Chemother; 2006 Sep; 58(3):693-6. PubMed ID: 16895940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves.
    Pathania R; Sharma SK
    Res Vet Sci; 2010 Aug; 89(1):108-12. PubMed ID: 20202656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absolute bioavailability of moxifloxacin.
    Ballow C; Lettieri J; Agarwal V; Liu P; Stass H; Sullivan JT
    Clin Ther; 1999 Mar; 21(3):513-22. PubMed ID: 10321420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration.
    Goudah A; Hasabelnaby S
    Res Vet Sci; 2010 Jun; 88(3):507-11. PubMed ID: 20004428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment.
    Barth J; Jäger D; Mundkowski R; Drewelow B; Welte T; Burkhardt O
    J Antimicrob Chemother; 2008 Sep; 62(3):575-8. PubMed ID: 18515790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations.
    Goudah A; Hasabelnaby S
    Chemotherapy; 2010; 56(1):26-31. PubMed ID: 20197659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose.
    Wacke R; Förster S; Adam U; Mundkowski RG; Klar E; Hopt UT; Drewelow B
    J Antimicrob Chemother; 2006 Nov; 58(5):994-9. PubMed ID: 16956903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration.
    Cárceles CM; Serrano JM; Marín P; Escudero E; Fernández-Varón E
    J Vet Med A Physiol Pathol Clin Med; 2006 Aug; 53(6):300-4. PubMed ID: 16901274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies.
    Mason JW; Florian JA; Garnett CE; Moon TE; Selness DS; Spaulding RR
    J Clin Pharmacol; 2010 Nov; 50(11):1249-59. PubMed ID: 20145260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.
    Stass H; Kubitza D
    J Antimicrob Chemother; 1999 May; 43 Suppl B():83-90. PubMed ID: 10382880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
    Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition kinetics of moxifloxacin in lactating ewes.
    Goudah A
    Vet J; 2008 Nov; 178(2):282-7. PubMed ID: 17900948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients.
    Kees MG; Weber S; Kees F; Horbach T
    J Antimicrob Chemother; 2011 Oct; 66(10):2330-5. PubMed ID: 21729931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats.
    Fernández-Varón E; Villamayor L; Escudero E; Espuny A; Cárceles CM
    Vet J; 2006 Sep; 172(2):302-7. PubMed ID: 15908243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penetration of moxifloxacin into liver tissue.
    Justinger C; Schilling MK; Kees MG; Kauffels A; Hirschmann K; Kopp B; Kees F; Kollmar O
    Int J Antimicrob Agents; 2012 Jun; 39(6):505-9. PubMed ID: 22526014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration.
    Zhang L; Li L; Shi W; Liu S; Liang X; Ye Z; Wang WJ; Zhang B; Li R; Chen Y; Yu C; Zhuo L; Wang X
    Int J Antimicrob Agents; 2013 Sep; 42(3):244-9. PubMed ID: 23876335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.